NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$31M

Net Income

-$28M

EPS (Diluted)

$-0.19

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$426M

Total Liabilities

$873M

Stockholders' Equity

-$447M

Cash & Equivalents

$241M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$31M	-$27M	-15.7%
Net Income	-$28M	-$27M	-4.4%

NMRA Q4 2022 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena